CELLTech Stroke™
CELLTech Stroke™
CELLTech Stroke™ is a deep brain stimulation system that aims to improve motor function in patients with permanent, moderate to severe disability due to subcortical ischemic stroke. CELLTech™ Stroke requires the same surgical procedure as the FDA-approved deep brain stimulator and as other DBS systems, applies microcurrents directly to brain tissue.
The proprietary CELLTech™ waveform has been carefully studied, designed and implemented for use in enhancing the natural reparative mechanism that is utilized in the brain post-stroke during a process known as spontaneous regeneration. This period of spontaneous regeneration takes place in the subacute stage of stroke and is the reason why some stroke victims show complete recovery. In some individuals, however, this process is incomplete. The mechanism of action of CELLTech™ Stroke is patented for the specific purpose of enhancing this process.
The CELLTech™ Advantage
The field of medicine has been trending towards a more diverse and balanced approach to patient care. This includes R&D efforts to market approve sustainable and patient-centered solutions that optimize safety and efficacy. Up to now, many medical treatments have been seen to have serious side effects, sometimes more harmful than the original disease or disorder itself — a problem in our healthcare field that needs to be addressed.
One solution currently being explored to take steps in the direction of a more effective medical field is to increase the use of technologies that have historically shown to have a better ratio of clinical benefit to clinical risk; for example: medical devices. CELLTech™ consists only of hardware and software, and therefore is scalable and easily standardized.
Next Generation Deep Brain Stimulation
CELLTech™ aims to give every patient back the quality of life and independence he or she has lost due to neurological tissue damage, while saving a substantial amount of money for the patient and his or her family. While, CELLTech Stroke™ has been designed and is pending clinical testing for use in treating motor function loss after stroke, additional indications are possible once market-approved for this first use in treating motor function loss. Our team, in collaboration with our clinical site, are now in the process of preparing and submitting an Investigative Device Exemption (IDE) to perform the necessary clinical testing to bring CELLTech™ to market.
CELLTech Stroke™ is a deep brain stimulation system that aims to improve motor function in patients with permanent, moderate to severe disability due to subcortical ischemic stroke. CELLTech™ Stroke requires the same surgical procedure as the FDA-approved deep brain stimulator and as other DBS systems, applies microcurrents directly to brain tissue.
The proprietary CELLTech™ waveform has been carefully studied, designed and implemented for use in enhancing the natural reparative mechanism that is utilized in the brain post-stroke during a process known as spontaneous regeneration. This period of spontaneous regeneration takes place in the subacute stage of stroke and is the reason why some stroke victims show complete recovery. In some individuals, however, this process is incomplete. The mechanism of action of CELLTech™ Stroke is patented for the specific purpose of enhancing this process.
The field of medicine has been trending towards a more diverse and balanced approach to patient care. This includes R&D efforts to market approve sustainable and patient-centered solutions that optimize safety and efficacy. Up to now, many medical treatments have been seen to have serious side effects, sometimes more harmful than the original disease or disorder itself — a problem in our healthcare field that needs to be addressed.
One solution currently being explored to take steps in the direction of a more effective medical field is to increase the use of technologies that have historically shown to have a better ratio of clinical benefit to clinical risk; for example: medical devices. CELLTech™ consists only of hardware and software, and therefore is scalable and easily standardized.
CELLTech™ aims to give every patient back the quality of life and independence he or she has lost due to neurological tissue damage, while saving a substantial amount of money for the patient and his or her family. While, CELLTech Stroke™ has been designed and is pending clinical testing for use in treating motor function loss after stroke, additional indications are possible once market-approved for this first use in treating motor function loss